Posted by Michael Wonder on 03 Dec 2025
Arrowhead Pharmaceuticals receives FDA breakthrough therapy designation for plozasiran in severe hypertriglyceridaemia
2 December 2025 - Arrowhead Pharmaceuticals today announced that the US FDA has granted breakthrough therapy designation to investigational plozasiran as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia (triglyceride levels greater than or equal to 500 mg/dL).
There are currently limited and inadequate treatment options for the millions of people globally living with severe hypertriglyceridaemia.
